Cargando…

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy and lacks effective therapeutic targets. Trametinib is considered to be a promising potential indirectly targeted KRAS inhibitor in PDAC. However, the clinical outcomes were poor. JQ1 displayed a significant synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaofei, Mao, Tiebo, Xu, Haiyan, Li, Shumin, Yue, Ming, Ma, Jingyu, Yao, Jiayu, Wang, Yongchao, Zhang, Xiao, Ge, Weiyu, Wang, Yanling, Shentu, Daiyuan, Wang, Liwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085242/ https://www.ncbi.nlm.nih.gov/pubmed/35468095 http://dx.doi.org/10.18632/aging.204031

Ejemplares similares

A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer
por: Ge, Weiyu, et al.
Publicado: (2022)

A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer
por: Ge, Weiyu, et al.
Publicado: (2022)

Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma
por: Xue, Shengbai, et al.
Publicado: (2022)

Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer
por: Xue, Shengbai, et al.
Publicado: (2022)

Cuproptosis‐related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients
por: Wang, Yanling, et al.
Publicado: (2023)

HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
por: Mao, Tiebo, et al.
Publicado: (2022)

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer
por: Ge, Weiyu, et al.
Publicado: (2022)

A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer
por: Yao, Jiayu, et al.
Publicado: (2021)

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells
por: Song, Qiaoling, et al.
Publicado: (2016)

CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway
por: Zhang, Xiao, et al.
Publicado: (2021)

Ras Downstream Effector GGCT Alleviates Oncogenic Stress
por: He, Zaoke, et al.
Publicado: (2019)

Characterization of DNA damage response deficiency in pancreatic cancer patients from China
por: Zhang, Xiaofei, et al.
Publicado: (2021)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
por: Cheng, Rongjie, et al.
Publicado: (2022)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
por: Yang, Zhang, et al.
Publicado: (2021)

Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
por: Tatli, Ozge, et al.
Publicado: (2021)

Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response
por: Wang, Yu, et al.
Publicado: (2021)

Structural impact of GTP binding on downstream KRAS signaling
por: Menyhárd, Dóra K., et al.
Publicado: (2020)

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras
por: Bahr, Julian C., et al.
Publicado: (2016)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Co-dependency of PKCδ and K-Ras: Inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer
por: Ohm, Angela M., et al.
Publicado: (2017)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes
por: Stephens, Robert M, et al.
Publicado: (2017)

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies
por: Kuracha, Murali R., et al.
Publicado: (2017)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS
por: Stelniec-Klotz, Iwona, et al.
Publicado: (2012)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines
por: Stubbs, Caleb K., et al.
Publicado: (2021)

DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
por: Miller, Abigail L., et al.
Publicado: (2023)

Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes
por: Dou, Yongchao, et al.
Publicado: (2016)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ta6hf2mhfleliughcs316pt3i